Price Disclosure Reductions for 2017 April Cycle
Page last updated: 23 January 2017
This summary of 1 April 2017 price disclosure reductions for the 2017 April Cycle only includes medicines taking a price disclosure reduction. The price disclosure legal determination mentioned at the bottom of this page includes brands where a weighted average disclosed price is determined but there will not be a price disclosure reduction (see Schedule 2 of the determination).
The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations).
The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Details about later publication of other prices are set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should understand that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2017 if the price of a component ingredient will be reduced on 1 April 2017, and flowing this reduced component price on to the combination item will result in a lower price than the direct reduction; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs. Letters will set out the new prices for F2 combination items and seek PB11a forms. F2 combination item pricing will require attention by affected companies during mid to late January 2017.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, are in the legal determination on the legislation.gov.au website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2016 PBS approved ex‑manufacturer price and the weighted average disclosed price for the 2017 April Cycle was below 10%. Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 30 September 2016 will also take the reduction on 1 April 2017 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was 5 pm AEDT on 22 December 2016.
Indicative prices for 1 April 2017 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2017. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 April 2017 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from early March 2017.
| Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) |
Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential April '17 PBS Price (AEMP) ($) per pharmaceutical item |
October '16 AEMP ($) |
Percentage difference between October '16 and April '17 PBS prices (AEMP) (%) per pharmaceutical item |
Calculations based on: O = all brand data G = originator brand data removed |
|---|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between October '16 AEMP & WADP = % Difference] | |||||||
| Alendronic acid | Oral | Tablet 70 mg (as alendronate sodium) | 4.56 | 20.22% | 3.64 | 4.06 | 10.34% | OWAPD |
| Amlodipine | Oral | Tablet 10 mg (as besylate) | 1.76 | 16.53% | 1.47 | 1.76 | 16.48% | GWAPD |
| Amlodipine | Oral | Tablet 5 mg (as besylate) | 1.00 | 16.53% | 0.83 | 1.00 | 17.00% | GWAPD |
| Anastrozole | Oral | Tablet 1 mg | 49.16 | 60.94% | 19.20 | 25.21 | 23.84% | GWAPD |
| Azathioprine | Oral | Tablet 25 mg | 14.16 | 20.10% | 11.31 | 14.16 | 20.13% | GWAPD |
| Azathioprine | Oral | Tablet 50 mg | 24.11 | 20.10% | 19.26 | 24.11 | 20.12% | GWAPD |
| Azithromycin* | Oral | Tablet 500 mg (as dihydrate) | 4.54 | 12.35% | 3.98 | 4.54 | 12.33% | GWAPD |
| Baclofen | Oral | Tablet 10 mg | 10.38 | 10.58% | 9.28 | 10.38 | 10.60% | GWAPD |
| Baclofen | Oral | Tablet 25 mg | 22.68 | 10.58% | 20.28 | 22.68 | 10.58% | GWAPD |
| Bisacodyl | Oral | Tablet 5 mg | 6.22 | 21.22% | 4.90 | 6.22 | 21.22% | OWAPD |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 10 mg | 16.63 | 32.81% | 11.17 | 13.01 | 14.14% | GWAPD |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 2.5 mg | 10.64 | 32.81% | 7.15 | 8.33 | 14.17% | GWAPD |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 5 mg | 13.30 | 32.81% | 8.94 | 10.41 | 14.12% | GWAPD |
| Calcitriol | Oral | Capsule 0.25 microgram | 17.12 | 12.43% | 14.99 | 17.12 | 12.44% | GWAPD |
| Candesartan | Oral | Tablet containing candesartan cilexetil 16 mg | 6.58 | 41.58% | 3.84 | 5.42 | 29.15% | GWAPD |
| Candesartan | Oral | Tablet containing candesartan cilexetil 32 mg | 7.95 | 41.58% | 4.64 | 6.56 | 29.27% | GWAPD |
| Candesartan | Oral | Tablet containing candesartan cilexetil 4 mg | 0.74 | 41.58% | 0.43 | 0.61 | 29.51% | GWAPD |
| Candesartan | Oral | Tablet containing candesartan cilexetil 8 mg | 2.20 | 41.58% | 1.29 | 1.81 | 28.73% | GWAPD |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 8.09 | 49.06% | 4.12 | 6.29 | 34.50% | GWAPD |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 9.46 | 49.06% | 4.82 | 7.48 | 35.56% | GWAPD |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 10.97 | 49.06% | 5.59 | 8.05 | 30.56% | GWAPD |
| Carvedilol | Oral | Tablet 12.5 mg | 13.12 | 23.64% | 10.02 | 13.12 | 23.63% | GWAPD |
| Carvedilol | Oral | Tablet 25 mg | 16.40 | 23.64% | 12.52 | 16.40 | 23.66% | GWAPD |
| Carvedilol | Oral | Tablet 6.25 mg | 10.49 | 23.64% | 8.01 | 10.49 | 23.64% | GWAPD |
| Celecoxib | Oral | Capsule 100 mg | 10.80 | 40.29% | 6.45 | 9.42 | 31.53% | OWAPD |
| Celecoxib | Oral | Capsule 200 mg | 10.80 | 40.29% | 6.45 | 9.42 | 31.53% | OWAPD |
| Ciprofloxacin | Oral | Tablet 250 mg (as hydrochloride) | 3.60 | 17.26% | 2.98 | 3.60 | 17.22% | GWAPD |
| Ciprofloxacin | Oral | Tablet 500 mg (as hydrochloride) | 7.03 | 17.26% | 5.82 | 7.03 | 17.21% | GWAPD |
| Ciprofloxacin | Oral | Tablet 750 mg (as hydrochloride) | 10.60 | 17.26% | 8.77 | 10.60 | 17.26% | GWAPD |
| Clarithromycin | Oral | Tablet 500 mg | 35.23 | 11.08% | 31.33 | 35.23 | 11.07% | GWAPD |
| Clindamycin | Oral | Capsule 150 mg (as hydrochloride) | 7.87 | 18.84% | 6.39 | 7.87 | 18.81% | GWAPD |
| Desvenlafaxine | Oral | Tablet (extended release) 100 mg (as succinate) | 22.65 | 28.09% | 16.29 | 22.65 | 28.08% | OWAPD |
| Desvenlafaxine | Oral | Tablet (extended release) 50 mg (as succinate) | 18.45 | 28.09% | 13.27 | 18.45 | 28.08% | OWAPD |
| Desvenlafaxine | Oral | Tablet (modified release) 100 mg | 22.65 | 28.09% | 16.29 | 22.65 | 28.08% | OWAPD |
| Desvenlafaxine | Oral | Tablet (modified release) 100 mg (as benzoate) | 22.65 | 28.09% | 16.29 | 22.65 | 28.08% | OWAPD |
| Desvenlafaxine | Oral | Tablet (modified release) 50 mg | 18.45 | 28.09% | 13.27 | 18.45 | 28.08% | OWAPD |
| Desvenlafaxine | Oral | Tablet (modified release) 50 mg (as benzoate) | 18.45 | 28.09% | 13.27 | 18.45 | 28.08% | OWAPD |
| Diclofenac | Oral | Tablet (enteric coated) containing diclofenac sodium 25 mg | 1.56 | 12.03% | 1.37 | 1.56 | 12.18% | GWAPD |
| Diclofenac | Oral | Tablet (enteric coated) containing diclofenac sodium 50 mg | 2.17 | 12.03% | 1.91 | 2.17 | 11.98% | GWAPD |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | 425.24 | 37.73% | 264.80 | 307.07 | 13.77% | OWAPD |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | 1012.48 | 37.73% | 630.47 | 731.11 | 13.77% | OWAPD |
| Electrolyte replacement, oral | Oral | Oral rehydration salts containing glucose 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10 | 5.25 | 14.86% | 4.47 | 5.25 | 14.86% | GWAPD |
| Escitalopram | Oral | Tablet 10 mg (as oxalate) | 2.73 | 28.43% | 1.95 | 2.35 | 17.02% | GWAPD |
| Escitalopram | Oral | Tablet 20 mg (as oxalate) | 2.75 | 28.43% | 1.97 | 2.38 | 17.23% | GWAPD |
| Esomeprazole | Oral | Capsule (enteric) 20 mg (as magnesium) | 12.58 | 18.80% | 10.21 | 12.58 | 18.84% | OWAPD |
| Esomeprazole | Oral | Capsule (enteric) 40 mg (as magnesium) | 21.33 | 18.80% | 17.32 | 21.33 | 18.80% | OWAPD |
| Esomeprazole | Oral | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | 12.58 | 18.80% | 10.21 | 12.58 | 18.84% | OWAPD |
| Esomeprazole | Oral | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | 21.33 | 18.80% | 17.32 | 21.33 | 18.80% | OWAPD |
| Exemestane | Oral | Tablet 25 mg | 71.67 | 27.98% | 51.62 | 58.26 | 11.40% | GWAPD |
| Felodipine | Oral | Tablet 10 mg (extended release) | 7.82 | 13.14% | 6.79 | 7.82 | 13.17% | GWAPD |
| Felodipine | Oral | Tablet 2.5 mg (extended release) | 3.00 | 13.14% | 2.61 | 3.00 | 13.00% | GWAPD |
| Felodipine | Oral | Tablet 5 mg (extended release) | 4.32 | 13.14% | 3.75 | 4.32 | 13.19% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 1.28 mg | 10.68 | 26.32% | 7.87 | 8.94 | 11.97% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 10.20 mg | 42.46 | 26.32% | 31.28 | 35.52 | 11.94% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 12.375 mg | 34.21 | 26.32% | 25.21 | 28.62 | 11.91% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 12.6 mg | 34.21 | 26.32% | 25.21 | 28.62 | 11.91% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 16.5 mg | 42.46 | 26.32% | 31.28 | 35.52 | 11.94% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 16.8 mg | 42.46 | 26.32% | 31.28 | 35.52 | 11.94% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 2.063 mg | 10.68 | 26.32% | 7.87 | 8.94 | 11.97% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 2.1 mg | 10.68 | 26.32% | 7.87 | 8.94 | 11.97% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 2.55 mg | 13.59 | 26.32% | 10.01 | 11.37 | 11.96% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 4.125 mg | 13.59 | 26.32% | 10.01 | 11.37 | 11.96% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 4.2 mg | 13.59 | 26.32% | 10.01 | 11.37 | 11.96% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 5.10 mg | 24.97 | 26.32% | 18.40 | 20.89 | 11.92% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 7.65 mg | 34.21 | 26.32% | 25.21 | 28.62 | 11.91% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 8.25 mg | 24.97 | 26.32% | 18.40 | 20.89 | 11.92% | GWAPD |
| Fentanyl | Transdermal | Transdermal patch 8.4 mg | 24.97 | 26.32% | 18.40 | 20.89 | 11.92% | GWAPD |
| Fludarabine | Injection | Powder for I.V. injection containing fludarabine phosphate 50 mg | 44.30 | 28.13% | 31.84 | 44.30 | 28.13% | OWAPD |
| Fludarabine | Injection | Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL | 221.52 | 28.13% | 159.21 | 221.52 | 28.13% | OWAPD |
| Fluoxetine | Oral | Capsule 20 mg (as hydrochloride) | 3.98 | 13.44% | 3.45 | 3.98 | 13.32% | GWAPD |
| Fluoxetine | Oral | Tablet, dispersible, 20 mg (as hydrochloride) | 3.98 | 13.44% | 3.45 | 3.98 | 13.32% | GWAPD |
| Gabapentin | Oral | Capsule 100 mg | 4.31 | 12.74% | 3.76 | 4.31 | 12.76% | GWAPD |
| Gabapentin | Oral | Capsule 300 mg | 14.39 | 12.74% | 12.56 | 14.39 | 12.72% | GWAPD |
| Gabapentin | Oral | Capsule 400 mg | 19.62 | 12.74% | 17.12 | 19.62 | 12.74% | GWAPD |
| Gabapentin | Oral | Tablet 600 mg | 31.15 | 12.74% | 27.18 | 31.15 | 12.74% | GWAPD |
| Gabapentin | Oral | Tablet 800 mg | 41.53 | 12.74% | 36.24 | 41.53 | 12.74% | GWAPD |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL | 87.33 | 19.31% | 70.47 | 87.33 | 19.31% | OWAPD |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL | 45.17 | 19.31% | 36.45 | 45.17 | 19.30% | OWAPD |
| Ipratropium | Inhalation | Nebuliser solution containing ipratropium bromide 250 micrograms (anhydrous) in 1 mL single dose units, 30 | 8.71 | 13.34% | 7.55 | 8.71 | 13.32% | GWAPD |
| Ipratropium | Inhalation | Nebuliser solution containing ipratropium bromide 500 micrograms (anhydrous) in 1 mL single dose units, 30 | 10.29 | 13.34% | 8.92 | 10.29 | 13.31% | GWAPD |
| Isosorbide mononitrate | Oral | Tablet 120 mg (sustained release) | 7.61 | 10.55% | 6.81 | 7.61 | 10.51% | GWAPD |
| Lamivudine with zidovudine | Oral | Tablet 150 mg-300 mg | 367.62 | 25.01% | 275.68 | 351.75 | 21.63% | GWAPD |
| Lamotrigine* | Oral | Tablet 100 mg | 17.71 | 18.87% | 14.37 | 17.71 | 18.86% | GWAPD |
| Lamotrigine* | Oral | Tablet 200 mg | 29.77 | 18.87% | 24.15 | 29.77 | 18.88% | GWAPD |
| Lamotrigine* | Oral | Tablet 25 mg | 6.38 | 18.87% | 5.18 | 6.38 | 18.81% | GWAPD |
| Lamotrigine* | Oral | Tablet 50 mg | 10.64 | 18.87% | 8.63 | 10.64 | 18.89% | GWAPD |
| Latanoprost | Application to the eye | Eye drops 50 micrograms per mL, 2.5 mL | 11.57 | 46.92% | 6.14 | 6.87 | 10.63% | GWAPD |
| Lisinopril | Oral | Tablet 10 mg | 3.50 | 14.11% | 3.01 | 3.50 | 14.00% | GWAPD |
| Lisinopril | Oral | Tablet 20 mg | 4.41 | 14.11% | 3.79 | 4.41 | 14.06% | GWAPD |
| Lisinopril | Oral | Tablet 5 mg | 2.34 | 14.11% | 2.01 | 2.34 | 14.10% | GWAPD |
| Meloxicam | Oral | Capsule 15 mg | 4.71 | 19.37% | 3.80 | 4.71 | 19.32% | GWAPD |
| Meloxicam | Oral | Capsule 7.5 mg | 3.23 | 19.37% | 2.60 | 3.23 | 19.50% | GWAPD |
| Meloxicam | Oral | Tablet 15 mg | 4.71 | 19.37% | 3.80 | 4.71 | 19.32% | GWAPD |
| Meloxicam | Oral | Tablet 7.5 mg | 3.23 | 19.37% | 2.60 | 3.23 | 19.50% | GWAPD |
| Metoprolol succinate | Oral | Tablet 190 mg (controlled release) | 63.06 | 10.21% | 56.62 | 63.06 | 10.21% | OWAPD |
| Metoprolol succinate | Oral | Tablet 23.75 mg (controlled release) | 8.55 | 10.21% | 7.68 | 8.55 | 10.18% | OWAPD |
| Metoprolol succinate | Oral | Tablet 47.5 mg (controlled release) | 40.37 | 10.21% | 36.25 | 40.37 | 10.21% | OWAPD |
| Metoprolol succinate | Oral | Tablet 95 mg (controlled release) | 50.45 | 10.21% | 45.30 | 50.45 | 10.21% | OWAPD |
| Mirtazapine | Oral | Tablet 15 mg | 2.62 | 14.84% | 2.23 | 2.62 | 14.89% | OWAPD |
| Mirtazapine | Oral | Tablet 15 mg (orally disintegrating) | 4.52 | 14.84% | 3.85 | 4.52 | 14.82% | OWAPD |
| Mirtazapine | Oral | Tablet 30 mg | 3.93 | 14.84% | 3.35 | 3.93 | 14.76% | OWAPD |
| Mirtazapine | Oral | Tablet 30 mg (orally disintegrating) | 6.02 | 14.84% | 5.13 | 6.02 | 14.78% | OWAPD |
| Mirtazapine | Oral | Tablet 45 mg | 6.55 | 14.84% | 5.58 | 6.55 | 14.81% | OWAPD |
| Mirtazapine | Oral | Tablet 45 mg (orally disintegrating) | 9.07 | 14.84% | 7.72 | 9.07 | 14.88% | OWAPD |
| Mitozantrone | Injection | Injection 20 mg (as hydrochloride) in 10 mL | 52.78 | 12.28% | 46.30 | 52.78 | 12.28% | OWAPD |
| Mitozantrone | Injection | Injection 25 mg (as hydrochloride) in 12.5 mL | 65.94 | 12.28% | 57.84 | 65.94 | 12.28% | OWAPD |
| Mometasone | Application | Cream containing mometasone furoate 1 mg per g, 15 g | 3.85 | 20.00% | 3.08 | 3.85 | 20.00% | GWAPD |
| Mometasone | Application | Lotion containing mometasone furoate 1 mg per g, 30 mL | 6.07 | 20.00% | 4.86 | 6.07 | 19.93% | GWAPD |
| Mometasone | Application | Ointment containing mometasone furoate 1 mg per g, 15 g | 3.85 | 20.00% | 3.08 | 3.85 | 20.00% | GWAPD |
| Montelukast | Oral | Tablet, chewable, 4 mg (as sodium) | 12.39 | 46.29% | 6.65 | 8.50 | 21.76% | GWAPD |
| Montelukast | Oral | Tablet, chewable, 5 mg (as sodium) | 11.65 | 46.29% | 6.26 | 7.99 | 21.65% | GWAPD |
| Nifedipine* | Oral | Tablet 20 mg | 6.40 | 10.83% | 5.71 | 6.40 | 10.78% | GWAPD |
| Nifedipine* | Oral | Tablet 20 mg (controlled release) | 6.65 | 10.83% | 5.93 | 6.65 | 10.83% | GWAPD |
| Nifedipine* | Oral | Tablet 30 mg (controlled release) | 7.19 | 10.83% | 6.41 | 7.19 | 10.85% | GWAPD |
| Nifedipine* | Oral | Tablet 60 mg (controlled release) | 9.03 | 10.83% | 8.05 | 9.03 | 10.85% | GWAPD |
| Olanzapine* | Oral | Tablet 10 mg | 19.15 | 38.24% | 11.83 | 13.56 | 12.76% | GWAPD |
| Olanzapine* | Oral | Tablet 10 mg (as benzoate) | 19.15 | 38.24% | 11.83 | 13.56 | 12.76% | GWAPD |
| Olanzapine* | Oral | Tablet 10 mg (orally disintegrating) | 19.15 | 38.24% | 11.83 | 13.56 | 12.76% | GWAPD |
| Olanzapine* | Oral | Tablet 15 mg (orally disintegrating) | 28.71 | 38.24% | 17.73 | 20.34 | 12.83% | GWAPD |
| Olanzapine* | Oral | Tablet 2.5 mg | 4.79 | 38.24% | 2.96 | 3.39 | 12.68% | GWAPD |
| Olanzapine* | Oral | Tablet 2.5 mg (as benzoate) | 4.79 | 38.24% | 2.96 | 3.39 | 12.68% | GWAPD |
| Olanzapine* | Oral | Tablet 20 mg (orally disintegrating) | 38.28 | 38.24% | 23.64 | 27.12 | 12.83% | GWAPD |
| Olanzapine* | Oral | Tablet 5 mg | 9.48 | 38.24% | 5.85 | 6.71 | 12.82% | GWAPD |
| Olanzapine* | Oral | Tablet 5 mg (as benzoate) | 9.48 | 38.24% | 5.85 | 6.71 | 12.82% | GWAPD |
| Olanzapine* | Oral | Tablet 5 mg (orally disintegrating) | 9.48 | 38.24% | 5.85 | 6.71 | 12.82% | GWAPD |
| Olanzapine* | Oral | Tablet 7.5 mg | 14.36 | 38.24% | 8.87 | 10.17 | 12.78% | GWAPD |
| Olanzapine* | Oral | Tablet 7.5 mg (as benzoate) | 14.36 | 38.24% | 8.87 | 10.17 | 12.78% | GWAPD |
| Olanzapine* | Oral | Wafer 10 mg | 19.15 | 38.24% | 11.83 | 13.56 | 12.76% | GWAPD |
| Olanzapine* | Oral | Wafer 15 mg | 28.71 | 38.24% | 17.73 | 20.34 | 12.83% | GWAPD |
| Olanzapine* | Oral | Wafer 5 mg | 9.48 | 38.24% | 5.85 | 6.71 | 12.82% | GWAPD |
| Omeprazole | Oral | Capsule 20 mg | 4.74 | 13.04% | 4.12 | 4.74 | 13.08% | GWAPD |
| Omeprazole | Oral | Tablet 10 mg (as magnesium) | 3.87 | 13.04% | 3.37 | 3.87 | 12.91% | GWAPD |
| Omeprazole | Oral | Tablet 20 mg | 4.74 | 13.04% | 4.12 | 4.74 | 13.08% | GWAPD |
| Omeprazole | Oral | Tablet 20 mg (as magnesium) | 4.74 | 13.04% | 4.12 | 4.74 | 13.08% | GWAPD |
| Pemetrexed | Injection | Powder for I.V. infusion 1 g (as disodium) | 3119.70 | 84.74% | 476.07 | 3119.70 | 84.74% | OWAPD |
| Pemetrexed | Injection | Powder for I.V. infusion 100 mg (as disodium) | 311.97 | 84.74% | 47.61 | 311.97 | 84.74% | OWAPD |
| Pemetrexed | Injection | Powder for I.V. infusion 500 mg (as disodium) | 1559.86 | 84.74% | 238.03 | 1559.86 | 84.74% | OWAPD |
| Pramipexole* | Oral | Tablet containing pramipexole hydrochloride 1 mg | 103.49 | 29.86% | 72.59 | 103.49 | 29.86% | GWAPD |
| Pramipexole* | Oral | Tablet containing pramipexole hydrochloride 125 micrograms | 3.62 | 29.86% | 2.54 | 3.62 | 29.83% | GWAPD |
| Pramipexole* | Oral | Tablet containing pramipexole hydrochloride 250 micrograms | 23.71 | 29.86% | 16.63 | 23.71 | 29.86% | GWAPD |
| Pravastatin | Oral | Tablet containing pravastatin sodium 10 mg | 1.72 | 16.76% | 1.43 | 1.72 | 16.86% | GWAPD |
| Pravastatin | Oral | Tablet containing pravastatin sodium 20 mg | 2.73 | 16.76% | 2.27 | 2.73 | 16.85% | GWAPD |
| Pravastatin | Oral | Tablet containing pravastatin sodium 40 mg | 4.24 | 16.76% | 3.53 | 4.24 | 16.75% | GWAPD |
| Pravastatin | Oral | Tablet containing pravastatin sodium 80 mg | 6.52 | 16.76% | 5.43 | 6.52 | 16.72% | GWAPD |
| Quinapril* | Oral | Tablet 10 mg (as hydrochloride) | 4.16 | 10.86% | 3.71 | 4.16 | 10.82% | GWAPD |
| Quinapril* | Oral | Tablet 20 mg (as hydrochloride) | 5.14 | 10.86% | 4.58 | 5.14 | 10.89% | GWAPD |
| Ranitidine | Oral | Tablet, effervescent, 150 mg (as hydrochloride) | 2.17 | 16.36% | 1.81 | 2.17 | 16.59% | GWAPD |
| Ranitidine | Oral | Tablet 150 mg (as hydrochloride) | 3.85 | 16.36% | 3.22 | 3.85 | 16.36% | GWAPD |
| Ranitidine | Oral | Tablet 300 mg (as hydrochloride) | 3.85 | 16.36% | 3.22 | 3.85 | 16.36% | GWAPD |
| Risperidone | Oral | Tablet 1 mg | 9.08 | 28.54% | 6.49 | 7.22 | 10.11% | GWAPD |
| Risperidone | Oral | Tablet 2 mg | 20.77 | 28.54% | 14.84 | 16.52 | 10.17% | GWAPD |
| Risperidone | Oral | Tablet 3 mg | 32.02 | 28.54% | 22.88 | 25.47 | 10.17% | GWAPD |
| Risperidone | Oral | Tablet 4 mg | 43.23 | 28.54% | 30.89 | 34.39 | 10.18% | GWAPD |
| Rizatriptan | Oral | Tablet (orally disintegrating) 10 mg (as benzoate) | 6.35 | 13.77% | 5.48 | 6.35 | 13.70% | OWAPD |
| Rizatriptan | Oral | Wafer 10 mg (as benzoate) | 6.35 | 13.77% | 5.48 | 6.35 | 13.70% | OWAPD |
| Rosuvastatin | Oral | Tablet 10 mg (as calcium) | 10.07 | 48.99% | 5.14 | 7.95 | 35.35% | GWAPD |
| Rosuvastatin | Oral | Tablet 20 mg (as calcium) | 14.33 | 48.99% | 7.31 | 11.32 | 35.42% | GWAPD |
| Rosuvastatin | Oral | Tablet 40 mg (as calcium) | 20.44 | 48.99% | 10.43 | 16.14 | 35.38% | GWAPD |
| Rosuvastatin | Oral | Tablet 5 mg (as calcium) | 6.86 | 48.99% | 3.50 | 5.41 | 35.30% | GWAPD |
| Sertraline | Oral | Tablet 100 mg (as hydrochloride) | 1.86 | 15.37% | 1.57 | 1.86 | 15.59% | GWAPD |
| Sertraline | Oral | Tablet 50 mg (as hydrochloride) | 1.86 | 15.37% | 1.57 | 1.86 | 15.59% | GWAPD |
| Sildenafil | Oral | Tablet 20 mg (as citrate) | 514.77 | 37.89% | 319.72 | 410.47 | 22.11% | OWAPD |
| Sotalol | Oral | Tablet containing sotalol hydrochloride 160 mg | 7.32 | 12.22% | 6.43 | 7.32 | 12.16% | GWAPD |
| Sotalol | Oral | Tablet containing sotalol hydrochloride 80 mg | 3.41 | 12.22% | 2.99 | 3.41 | 12.32% | GWAPD |
| Tacrolimus* | Oral | Capsule 0.5 mg | 125.07 | 12.29% | 109.70 | 125.07 | 12.29% | GWAPD |
| Tacrolimus* | Oral | Capsule 1 mg | 250.14 | 12.29% | 219.40 | 250.14 | 12.29% | GWAPD |
| Tacrolimus* | Oral | Capsule 1 mg (once daily prolonged release) | 150.08 | 12.29% | 131.64 | 150.08 | 12.29% | GWAPD |
| Tacrolimus* | Oral | Capsule 5 mg | 625.04 | 12.29% | 548.22 | 625.04 | 12.29% | GWAPD |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 40 mg-12.5 mg | 4.45 | 52.25% | 2.12 | 3.67 | 42.23% | GWAPD |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 80 mg-12.5 mg | 11.08 | 52.25% | 5.29 | 8.65 | 38.84% | GWAPD |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 80 mg-25 mg | 12.07 | 52.25% | 5.76 | 9.94 | 42.05% | GWAPD |
| Terbinafine | Oral | Tablet 250 mg (as hydrochloride) | 22.12 | 20.47% | 17.59 | 22.12 | 20.48% | GWAPD |
| Tirofiban | Injection | Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL | 264.60 | 23.18% | 203.27 | 232.19 | 12.46% | OWAPD |
| Topotecan | Injection | Powder for I.V. infusion 4 mg (as hydrochloride) | 45.33 | 29.23% | 32.08 | 45.33 | 29.23% | OWAPD |
| Tramadol* | Oral | Tablet (sustained release) containing tramadol hydrochloride 100 mg | 2.53 | 11.65% | 2.24 | 2.53 | 11.46% | GWAPD |
| Tramadol* | Oral | Tablet (sustained release) containing tramadol hydrochloride 150 mg | 3.40 | 11.65% | 3.00 | 3.40 | 11.76% | GWAPD |
| Tramadol* | Oral | Tablet (sustained release) containing tramadol hydrochloride 200 mg | 4.14 | 11.65% | 3.66 | 4.14 | 11.59% | GWAPD |
| Trimethoprim with sulfamethoxazole | Oral | Tablet 160 mg-800 mg | 2.28 | 22.60% | 1.76 | 2.28 | 22.81% | GWAPD |
| Valaciclovir | Oral | Tablet 500 mg (as hydrochloride) | 8.40 | 37.65% | 5.24 | 6.37 | 17.74% | GWAPD |
| Zoledronic acid | Injection | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | 326.97 | 24.97% | 245.33 | 326.97 | 24.97% | OWAPD |
| Zoledronic acid | Injection | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | 326.97 | 24.97% | 245.33 | 326.97 | 24.97% | OWAPD |
| Zoledronic acid | Injection | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | 437.77 | 24.97% | 328.46 | 437.77 | 24.97% | OWAPD |
